Aztreonam
As of the edition of 20 October 2026, Aztreonam is a small molecule: marketed, first approved in 1986 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Azactam
- First approved
- 16 December 1986 (CH)
- Approvals on record
- 13 in 5 regions
- Holder of the most recent approval
- AbbVie; 8 holders in all
- Registered trials
- 34, 4 stopped early
- Disease areas
- Infections; Lungs and airways; Digestive system; Inherited and neonatal; Urinary and reproductive; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 2 | 3 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 6 | 4 | 1 | 1 |
| Phase 3 | 14 | 11 | 1 | 2 |
| Phase 4 | 3 | 2 | 0 | 1 |
| All trials | 34 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Earlier holder | 1986 to now |
| Pfizer | Later holder and Lead sponsor of trials | 2002 to now |
| Gilead Sciences | Applicant, Later holder and Lead sponsor of trials | 2003 to now |
| Laboratoires Delbert | Acquired holder | 2026 to now |